Which Treatment Fits Your Week 13-16 Weight Management Goals?
1.7 Wegovy vs Mounjaro: Mechanism and Dosing Differences
The 1.7mg Wegovy dose represents weeks 13-16 of your escalation journey, targeting GLP-1 receptors to reduce appetite and promote satiety after smaller meals. Mounjaro (tirzepatide) takes a different approach, activating both GIP and GLP-1 receptor pathways, potentially offering enhanced glucose control alongside weight management benefits. At this stage, Wegovy patients are approaching their penultimate dose before 2.4mg maintenance, while Mounjaro users typically progress through 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg options. The key difference lies in Mounjaro's dual-pathway mechanism versus Wegovy's focused GLP-1 approach, both requiring clinical assessment for prescription-only medicine supply.
Your treatment choice at the 1.7mg Wegovy equivalent stage depends on several factors including previous tolerance, weight management goals, and any concurrent diabetes management needs. Mounjaro's broader dose range may suit patients requiring more granular escalation, whilst 1.7mg Wegovy provides a proven pathway toward the established 2.4mg maintenance dose. Both treatments require ongoing commitment alongside a reduced-calorie diet and increased physical activity. EverydayMeds dispenses both options through our GPhC #9012878 registered pharmacy, ensuring your prescriber can access either treatment based on your individual clinical needs.
1.7 Wegovy Pricing vs Mounjaro Cost Comparison
Our 1.7mg Wegovy costs £139.99 per pen, positioning it competitively against equivalent-stage Mounjaro pricing at similar treatment phases. Returning customers apply code DOSE25 at checkout to access this pricing, while new patients use FIRST40 for their initial orders. The Elevate Duo bundle combining 1.7mg and 2.4mg Wegovy costs £369.99, providing seamless transition to maintenance dosing. For patients requiring extended 1.7mg stabilisation, our Consistency 1.7mg bundle offers two pens for £309.99. Both treatments require the same clinical assessment process, prescriber review, and temperature-controlled delivery, ensuring equivalent service standards regardless of your choice.
When comparing long-term costs, consider that 1.7mg Wegovy users typically advance to 2.4mg maintenance within four weeks, while Mounjaro patients may require several additional escalation steps depending on tolerance and response. Our transparent pricing eliminates hidden costs, with next-day cold-chain delivery included in all pen prices. The clinical assessment takes just three minutes online, followed by prescriber review within three working days (or 24 hours with express service). Both treatments qualify for the same professional clinical support from our dispensing team, ensuring your weight management investment receives comprehensive pharmaceutical care throughout your treatment journey.
Clinical Evidence: STEP Trials vs SURPASS Studies for 1.7 Wegovy
In the landmark STEP 1 trial, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, with many participants reaching significant milestones during the 1.7mg phase. The Wilding et al., NEJM, 2021 publication demonstrated sustained weight management throughout the dose escalation period, including the crucial weeks 13-16 covered by 1.7mg dosing. These results support the structured escalation approach, with 1.7mg representing an important stepping stone toward maintenance therapy. The STEP programme enrolled patients with BMI ≥30 or ≥27 with weight-related comorbidities, matching current UK licensing criteria.
Mounjaro's SURPASS trials focused primarily on diabetes management, with weight loss observed as a secondary benefit in many studies. Direct comparison of trial results isn't clinically meaningful due to different study populations, endpoints, and trial designs between the STEP and SURPASS programmes. Both treatments demonstrated efficacy in their respective clinical programmes, supporting their current UK licensing for weight management. Your prescriber can evaluate which clinical evidence profile best matches your individual treatment goals and medical history during the assessment process.
How 1.7 Wegovy Works in Your Body
The 1.7mg Wegovy dose delivers semaglutide, a GLP-1 receptor agonist that mimics your body's natural incretin hormones responsible for appetite regulation and glucose homeostasis. Once injected weekly, semaglutide binds to GLP-1 receptors in your brain's appetite centres, reducing food cravings and promoting earlier satiety during meals. This mechanism becomes particularly effective at the 1.7mg dose level, where many patients report significant changes in their relationship with food and eating patterns. The medication also slows gastric emptying, helping you feel fuller for longer periods after eating smaller portions. Unlike oral appetite suppressants, Wegovy's injectable format ensures consistent absorption and sustained action throughout the weekly dosing interval, supporting steady progress during weeks 13-16 of treatment.
Ordering 1.7 Wegovy Through EverydayMeds
Your 1.7mg Wegovy order begins with our three-minute online clinical assessment, covering your weight management history, current medications, and treatment goals at this advanced escalation stage. Our qualified prescribers review your assessment within three working days (24 hours with express service), ensuring appropriate continuation of your dose escalation journey. Once approved, your prescription-only medicine ships via next-day delivery in temperature-controlled packaging, maintaining the cold-chain integrity essential for semaglutide stability. We include comprehensive injection instructions, disposal guidance, and direct access to our clinical support team for any treatment questions. Our GPhC #9012878 registration ensures full regulatory compliance throughout the dispensing process, from initial assessment through ongoing pharmaceutical care.
Storage and Practical Considerations for 1.7 Wegovy
Your 1.7mg Wegovy pen requires refrigeration at 2-8°C before first use, but offers significant practical advantages with up to six weeks stability at room temperature below 30°C once removed from the fridge. This storage flexibility surpasses Mounjaro's 21-day room temperature limit, making 1.7mg Wegovy more suitable for travel, work schedules, or lifestyle flexibility during weeks 13-16. The FlexTouch pen design ensures accurate dosing with clear dose confirmation, important for maintaining precise escalation protocols. Each pen contains four doses, supporting the weekly injection schedule throughout your month-long 1.7mg phase. Proper disposal through your local pharmacy's sharps collection service maintains environmental safety standards for prescription-only medicine waste.
Why Week 13-16 Makes 1.7 Wegovy vs Mounjaro Comparison Crucial
The 1.7mg Wegovy phase represents your penultimate dose before reaching 2.4mg maintenance, making treatment comparison particularly relevant at this stage. Many patients experience accelerated weight management progress during weeks 13-16, as cumulative semaglutide effects combine with established lifestyle changes. This timing often coincides with plateaus or side effect concerns that might prompt consideration of alternative treatments like Mounjaro. The structured nature of Wegovy's escalation means you're just four weeks from maintenance therapy, while switching to Mounjaro would require starting their separate escalation protocol.
Cost optimisation becomes increasingly important as you approach long-term maintenance therapy, making the 1.7mg stage ideal for evaluating treatment sustainability and value. Our Elevate Duo bundle (1.7mg + 2.4mg for £369.99) provides seamless transition to maintenance, while Mounjaro's extended dose range might require multiple additional escalation steps. Both treatments remain available through EverydayMeds, ensuring your prescriber can adjust your therapy based on weeks 13-16 response patterns. The investment in either treatment at this stage supports long-term weight management success, with your choice guided by individual tolerance, progress, and lifestyle factors.
Complete Your 1.7 Wegovy Order Today
Ready to continue your weight management journey with 1.7mg Wegovy at £139.99, or explore Mounjaro alternatives through our comprehensive clinical assessment? Returning customers use code DOSE25 at checkout, while new patients apply FIRST40 during their first order. Our qualified prescribers evaluate both treatment options during your assessment, ensuring optimal therapy selection for weeks 13-16 and beyond. The Elevate Duo bundle provides smooth transition to maintenance therapy, supporting your long-term weight management investment. Both Wegovy and Mounjaro remain available through our GPhC-registered pharmacy, with next-day delivery and comprehensive clinical support throughout your treatment journey.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
